DDInter1355 DDInter298
Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Oxaliplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Carboplatin
Oxaliplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Platinum-containing Compounds {u} (Pharmacologic Class) includes {v} (Compound) Carboplatin
Oxaliplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) is associated with {v} (Disease) urinary bladder cancer
urinary bladder cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Oxaliplatin {u} (Compound) binds {v} (Gene) ATP7A
ATP7A {u} (Gene) interacts with {v} (Gene) ATP7B
ATP7B {u} (Gene) is bound by {v} (Compound) Carboplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cisplatin
Cisplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Oxaliplatin {u} (Compound) binds {v} (Gene) SOD1
SOD1 {u} (Gene) regulates {v} (Gene) MT2A
MT2A {u} (Gene) is bound by {v} (Compound) Carboplatin
Oxaliplatin {u} (Compound) binds {v} (Gene) MT2A
MT2A {u} (Gene) is regulated by {v} (Gene) SOD1
SOD1 {u} (Gene) is bound by {v} (Compound) Carboplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methotrexate
Methotrexate {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Oxaliplatin {u} (Compound) binds {v} (Gene) ATP7B
ATP7B {u} (Gene) interacts with {v} (Gene) ATP7A
ATP7A {u} (Gene) is bound by {v} (Compound) Carboplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Capecitabine
Capecitabine {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Venous thrombosis {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Oxaliplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) is bound by Carboplatin (Compound)
Oxaliplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class) and Platinum-containing Compounds (Pharmacologic Class) includes Carboplatin (Compound)
Oxaliplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) is associated with urinary bladder cancer (Disease) and urinary bladder cancer (Disease) is treated by Carboplatin (Compound)
Oxaliplatin (Compound) binds ATP7A (Gene) and ATP7A (Gene) interacts with ATP7B (Gene) and ATP7B (Gene) is bound by Carboplatin (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Oxaliplatin (Compound) binds SOD1 (Gene) and SOD1 (Gene) regulates MT2A (Gene) and MT2A (Gene) is bound by Carboplatin (Compound)
Oxaliplatin (Compound) binds MT2A (Gene) and MT2A (Gene) is regulated by SOD1 (Gene) and SOD1 (Gene) is bound by Carboplatin (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Oxaliplatin (Compound) binds ATP7B (Gene) and ATP7B (Gene) interacts with ATP7A (Gene) and ATP7A (Gene) is bound by Carboplatin (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and Capecitabine (Compound) causes Venous thrombosis (Side Effect) and Venous thrombosis (Side Effect) is caused by Carboplatin (Compound)